The estimated Net Worth of Maurice Zauderer is at least $16.8 Million dollars as of 27 January 2022. Dr Zauderer owns over 1,801,801 units of Vaccinex Inc stock worth over $16,440,471 and over the last 6 years he sold VCNX stock worth over $0. In addition, he makes $357,265 as Co-Founder, CEO, and Pres & Director at Vaccinex Inc.
Dr has made over 3 trades of the Vaccinex Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 1,801,801 units of VCNX stock worth $1,999,999 on 27 January 2022.
The largest trade he's ever made was buying 1,801,801 units of Vaccinex Inc stock on 27 January 2022 worth over $1,999,999. On average, Dr trades about 173,655 units every 76 days since 2019. As of 27 January 2022 he still owns at least 2,899,554 units of Vaccinex Inc stock.
You can see the complete history of Dr Zauderer stock trades at the bottom of the page.
Dr. Maurice Zauderer Ph.D. is the Co-Founder, CEO, Pres & Director at Vaccinex Inc.
As the Co-Founder, CEO, and Pres & Director of Vaccinex Inc, the total compensation of Dr D at Vaccinex Inc is $357,265. There are no executives at Vaccinex Inc getting paid more.
Dr D is 75, he's been the Co-Founder, CEO, and Pres & Director of Vaccinex Inc since . There are no older and 5 younger executives at Vaccinex Inc.
Maurice's mailing address filed with the SEC is C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER, NY, 14620.
Over the last 6 years, insiders at Vaccinex Inc have traded over $3,161 worth of Vaccinex Inc stock and bought 14,062,785 units worth $29,583,294 . The most active insiders traders include Albertfcmi Parent Co. Fried..., Maurice Zauderer, and Maurice Vaccinex (Rochester.... On average, Vaccinex Inc executives and independent directors trade stock every 61 days with the average trade being worth of $2,417,268. The most recent stock trade was executed by Albertfcmi Parent Co. Fried... on 9 August 2024, trading 100 units of VCNX stock currently worth $451.
located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop
Vaccinex Inc executives and other stock owners filed with the SEC include: